SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-23-015020
Filing Date
2023-04-27
Accepted
2023-04-27 08:31:29
Documents
7
Period of Report
2023-06-13

Document Format Files

Seq Description Document Type Size
1 DEF 14A inzy_2023_proxy_stmt_def.htm DEF 14A 1187757
2 GRAPHIC img185880420_0.jpg GRAPHIC 46249
3 GRAPHIC img185880420_1.jpg GRAPHIC 5626
4 GRAPHIC img185880420_2.jpg GRAPHIC 46249
5 GRAPHIC img185880420_3.jpg GRAPHIC 5813
6 GRAPHIC img185880420_4.jpg GRAPHIC 596644
7 GRAPHIC img185880420_5.jpg GRAPHIC 329384
  Complete submission text file 0000950170-23-015020.txt   2608072
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Filer) CIK: 0001693011 (see all company filings)

IRS No.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39397 | Film No.: 23852110
SIC: 2834 Pharmaceutical Preparations